Statement of problem

Botulinum toxin has been used for various therapeutic and esthetic purposes for nearly 4 decades and has shown positive outcomes in patients with bruxism. However, the effectiveness of botulinum toxin injections as an alternative to traditional therapies in the management of primary bruxism is still unclear.

Purpose

The purpose of this systematic review was to analyze the clinical outcomes of the use of botulinum toxin type A injections in the management of primary bruxism in adults.

Material and methods

Databases such as PubMed, Web of Science, Scopus, LILIACS, Cochrane Library, and Open Grey Literature were searched without language or date restrictions until October 6, 2019. Using Mendeley Desktop software to organize the references, 2 independent researchers selected the published clinical studies (Study type) on the improvement of symptoms (Outcome) in human adults with primary bruxism (Participants/Population) who received botulinum toxin type A injections (Intervention), placebo injections, saline injections, no injections, or other treatments (Comparator(s)/Control) for the management of bruxism.

Results

A total of 601 references were initially obtained from the 6 databases. Six randomized clinical trials and 4 case series were selected and critically appraised according to the Fowkes and Fulton guidelines. Heterogeneity among the studies did not allow for a meta-analysis. All studies supported the efficacy and safety of botulinum toxin injections in reducing the symptoms of primary bruxism.

Conclusions

Botulinum toxin type A injections are effective in the treatment of the symptoms of primary bruxism in adults. Randomized clinical trials are still needed to establish a protocol for using botulinum toxin as an alternative to traditional therapies in the management of primary bruxism.

中文翻译：

---

A型肉毒杆菌毒素注射治疗成人原发性磨牙症的临床结果：系统评价

问题陈述

肉毒杆菌毒素已用于各种治疗和美容目的近 4 年，并在磨牙症患者中显示出积极的结果。然而，肉毒杆菌毒素注射作为传统疗法替代治疗原发性磨牙症的有效性仍不清楚。

目的

本系统评价的目的是分析使用 A 型肉毒杆菌毒素注射治疗成人原发性磨牙症的临床结果。

材料与方法

PubMed、Web of Science、Scopus、LILIACS、Cochrane 图书馆和 Open Gray 文献等数据库在 2019 年 10 月 6 日之前不受语言或日期限制。使用 Mendeley Desktop 软件组织参考文献，2 位独立研究人员选择了已发表的临床研究（研究类型）关于接受 A 型肉毒杆菌毒素注射（干预）、安慰剂注射、盐水注射、不注射或其他治疗（比较者）的成人原发性磨牙症（参与者/人群）症状（结果）的改善)/Control) 用于治疗磨牙症。

结果

最初从 6 个数据库中获得了总共 601 篇参考文献。根据 Fowkes 和 Fulton 指南，选择并严格评估了 6 项随机临床试验和 4 个病例系列。研究之间的异质性不允许进行荟萃分析。所有研究都支持肉毒杆菌毒素注射在减轻原发性磨牙症症状方面的有效性和安全性。

结论

A型肉毒杆菌毒素注射可有效治疗成人原发性磨牙症的症状。仍然需要进行随机临床试验，以建立使用肉毒杆菌毒素替代传统疗法来治疗原发性磨牙症的方案。